Actively Recruiting
Study of Gastroesophageal Reflux Symptoms in Children Aged 2 to 18 With Cystic Fibrosis
Led by Duke University · Updated on 2025-12-19
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying gastroesophageal reflux disease GERD symptoms in children aged 2 to 18 years who have cystic fibrosis CF. The study aims to understand how common GERD symptoms are in these pediatric patients using the Gastroesophageal Symptom Assessment Scale GSAS and to evaluate the effects of stopping anti-GERD therapy on these symptoms. This research is sponsored by Duke University and seeks to provide insights into GERD management in children with CF. Participants will complete the GSAS questionnaire at the start of the study. Those currently receiving GERD therapy will stop their medication at enrollment, and their symptoms will be reassessed with the GSAS 12 weeks later. Children not on GERD therapy will only complete the GSAS at baseline. The study includes two groups children with CF on GERD therapy without severe GERD and children with CF not receiving GERD therapy. During the study, children will be monitored for changes in their GSAS scores to assess GERD symptom severity before and after stopping GERD treatment. The main outcomes measured are the change in GSAS scores from baseline to 12 weeks in children who stop GERD medication, as well as average GSAS scores at baseline for children on and off GERD therapy. The total study participation will last at least 12 weeks after the initial assessment for those discontinuing therapy.
CONDITIONS
Brief Title
GERD in Children With Cystic Fibrosis
Research Team
Y
Yara Salameh, MF
S
Shatha Yousef, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here